Cargando…

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma

BACKGROUND: Despite aggressive upfront treatment in glioblastoma (GBM), recurrence remains inevitable for most patients. Accumulating evidence has identified hypermutation induced by temozolomide (TMZ) as an emerging subtype of recurrent GBM. However, its biological and therapeutic significance has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daniel, Paul, Meehan, Brian, Sabri, Siham, Jamali, Fatemeh, Sarkaria, Jann N, Choi, Dongsic, Garnier, Delphine, Kitange, Gaspar, Glennon, Kate I, Paccard, Antoine, Karamchandani, Jason, Riazalhosseini, Yasser, Rak, Janusz, Abdulkarim, Bassam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252128/ https://www.ncbi.nlm.nih.gov/pubmed/35795471 http://dx.doi.org/10.1093/noajnl/vdac076

Ejemplares similares

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
por: Daniel, Paul, et al.
Publicado: (2019)

TRANSLATIONAL RESEARCH-03 MULTIPLE MECHANISMS MODULATE TEMOZOLOMIDE RESISTANCE AND ARE POTENTIAL TARGETS FOR GLIOBLASTOMA THERAPY.
por: Kitange, Gaspar, et al.
Publicado: (2023)

Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells
por: Harder, Bryan G., et al.
Publicado: (2019)

Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma
por: Glennon, Kate I., et al.
Publicado: (2021)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132)
por: Faye, Mame Daro, et al.
Publicado: (2021)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells
por: Nagel, Zachary D., et al.
Publicado: (2019)

Oncogenic RAS drives the CRAF‐dependent extracellular vesicle uptake mechanism coupled with metastasis
por: Choi, Dongsic, et al.
Publicado: (2021)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic
por: Bian, David J. H., et al.
Publicado: (2022)

OPTC-5. Molecular signatures of podoplanin expressing glioblastoma cell subsets with putative role in cancer associated thrombosis and microthrombosis
por: Tawil, Nadim, et al.
Publicado: (2021)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
por: Gupta, Shiv K., et al.
Publicado: (2019)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma
por: Chaddad, Ahmad, et al.
Publicado: (2019)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
por: Hirst, T C, et al.
Publicado: (2013)

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy
por: Guillevin, R, et al.
Publicado: (2011)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts
por: Porath, Kendra A, et al.
Publicado: (2022)

Extracellular Vesicles as Conduits of Non-Coding RNA Emission and Intercellular Transfer in Brain Tumors
por: Spinelli, Cristiana, et al.
Publicado: (2018)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Oncogenic extracellular vesicles in brain tumor progression
por: D’Asti, Esterina, et al.
Publicado: (2012)

Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice
por: Cho, Hee-Yeon, et al.
Publicado: (2020)

O(6)-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts
por: Clemons, M, et al.
Publicado: (2005)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
por: Daniel, R A, et al.
Publicado: (2010)

Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide
por: Conway, Gillian E, et al.
Publicado: (2016)

Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer
por: Lesniak, David, et al.
Publicado: (2013)

Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
por: Han, Sheng, et al.
Publicado: (2017)

Cannabidiol inhibits RAD51 and sensitizes glioblastoma to temozolomide in multiple orthotopic tumor models
por: Soroceanu, Liliana, et al.
Publicado: (2022)

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma
por: Khan, Muhammad Babar, et al.
Publicado: (2021)

Quantitative proteomics and biological activity of extracellular vesicles engineered to express SARS‐CoV‐2 spike protein
por: Choi, Dongsic, et al.
Publicado: (2022)

Spectral flow cytometry identifies distinct nonneoplastic plasma extracellular vesicle phenotype in glioblastoma patients
por: Aibaidula, Abudumijiti (Zack), et al.
Publicado: (2023)

EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand
por: Hoogstrate, Youri, et al.
Publicado: (2019)

TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT
por: Nie, Er, et al.
Publicado: (2020)

XAF1 directs glioma response to temozolomide through apoptotic transition of autophagy by activation of ATM–AMPK signaling
por: Lee, Min-Goo, et al.
Publicado: (2022)

Human multipotent mesenchymal stromal cells cytokine priming promotes RAB27B-regulated secretion of small extracellular vesicles with immunomodulatory cargo
por: Cheng, Anastasia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_leak60th7gtff1cr1e95ud8lpi